Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Agenus chooses NewVac to develop and sell Oncophage in Russia

Executive Summary

Agenus Inc. (cancer and infectious disease therapeutics) has granted NewVac LLC (oncology immunotherapeutics; incubated at ChemRar High Tech Center) exclusive rights to develop, manufacture, and commercialize the personalized cancer vaccine Oncophage (vitespan) in Russia.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies